Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Expert Review of Molecular Diagnostics|May 14, 2015
MET/HGF pathway in multiple myeloma: from diagnosis to targeted therapy?Manuela Gambella, Antonio Palumbo, Alberto Rocci
Expert Opinion on Biological Therapy|August 11, 2017
Systemic virotherapy for multiple myelomaStefania Oliva, Manuela Gambella, Mario Boccadoro, et al.
Annals of Clinical and Translational Neurology|October 8, 2025
Interleukin-6 as a Key Biomarker in Facioscapulohumeral Dystrophy: Evidence From Longitudinal AnalysesJonathan Pini, Emanuela Martinuzzi, Sandra Dhifallah, et al.
Journal of Translational Medicine|December 13, 2012
Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myelomaGiuseppina Bonanno, Andrea Mariotti, Annabella Procoli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2020
Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation SequencingMattia D'Agostino, Gian Maria Zaccaria, Bachisio Ziccheddu, et al.
The Journal of Molecular Diagnostics : JMD|August 31, 2015
Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCRDaniela Drandi, Lenka Kubiczkova-Besse, Simone Ferrero, et al.
British Journal of Haematology|January 24, 2014
MET dysregulation is a hallmark of aggressive disease in multiple myeloma patientsAlberto Rocci, Manuela Gambella, Simona Aschero, et al.
Oncotarget|October 26, 2016
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysisStefania Oliva, Manuela Gambella, Milena Gilestro, et al.
Neuromuscular Disorders : NMD|March 20, 2026
Late-onset facioscapulohumeral muscular dystrophy defines a distinct clinical subgroupGiulia Tammam, Sandra Dhifallah, Hongmei Yang, et al.
Pageof 2